Pollock C, et al. - In this double-blind, placebo-controlled trial (DELIGHT), researchers evaluated the albuminuria-lowering impact of dapagliflozin with and without the saxagliptin, and the impact of dapagliflozin–saxagliptin on glycemic control in type 2 diabetes and moderate-to-severe chronic kidney disease. After a 4-week, single-blind, placebo run-in period, participants were randomized (1:1:1; via an interactive voice–web response system) to receive either dapagliflozin (10 mg) only, dapagliflozin (10 mg) and saxagliptin (2.5 mg), or once-daily placebo for 24 weeks. Overall, dapagliflozin treatment with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, was found to be a viable option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.